v3.25.2
Revenues
 6 Months Ended
Jun. 30, 2025
Revenues [Abstract]  
Revenues
2.Revenues

 

   For the three months
ended June 30,		   For the six months
ended June 30,		 
   2025
(unaudited)		   2024
(unaudited)		   2025
(unaudited)		   2024
(unaudited)		 
       (in €)     
Revenues   39,432    6,357    39,432    42,394 
Total   39,432    6,357    39,432    42,394 

 

For the three months ended June 30, 2025 and 2024, the Company realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €39 thousand and €6 thousand, respectively.

 

For the six months ended June 30, 2025 and 2024, the Company realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €39 thousand and €42 thousand, respectively.

 

Revenues reported are sales to end customers (hospitals). Sales to distributors do not constitute revenue for the Company under IFRS 15. All revenues are attributed to sales made in the United States.